Culture

Piper Jaffray Companies Reiterates "Overweight" Rating for Alnylam Pharmaceuticals, Inc. (ALNY)

Piper Jaffray Companies Reiterates

TIAA CREF Investment Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. This represents a change from most recent open price of 5.88%. Perceptive Advisors has an ownership of 1,103,475 stocks of the biopharmaceutical firms shares valued $56,553,000 following purchasing an extra 985,000 shares through out the quarter. As of quarter end Janus Capital Management LLC had bought a total of 136,469 shares growing its holdings by 26.6%.

A number of other brokerages also recently issued reports on ALNY.

Artal Gp Sa invested 0.42% of its portfolio in Alnylam Pharmaceuticals, Inc. Lastly, Russell Investments Group upgraded its stake in stocks of Alnylam Pharmaceuticals by 341.1% in the 1st period.

Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. Neuberger Berman Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $205,000. Finally, Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 2.9% in the second quarter. Institutional investors and hedge funds own 89.71% of the company's stock. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/09/10/barclays-plc-reaffirms-overweight-rating-for-alnylam-pharmaceuticals-inc-alny.html. (NASDAQ:ALNY) traded up 1.13% during mid-day trading on Tuesday, hitting $43.99. The company was maintained on Wednesday, April 12 by RBC Capital Markets. The stock is trading $81.46 its 50-day moving average by 7.77%.

14-day Williams %R for Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, November 2nd. Analysts are forecasting earnings of $-1.18 on a per share basis this quarter. The company's end of quarter revenue went up 82.9% compared with the same period in the prior year. Last session Alnylam Pharmaceuticals, Inc. Analysts expect next quarter's EPS will be $-1.35 with next year's EPS projected to be $-5.33.

Now we will discuss the financial strength of Alnylam Pharmaceuticals, Inc. OraSure Technologies had 15 analyst reports since August 6, 2015 according to SRatingsIntel. Chardan Capital reissued a "buy" rating and set a $124.00 price target (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Needham & Company LLC downgraded Alnylam Pharmaceuticals to a "buy" rating and lowered their price objective for the company from $152.00 to $137.00 in a research report on Thursday, October 6th. Vetr downgraded Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $71.50 price objective for the company.in a research note on Monday, May 15th. Jefferies maintained it with "Buy" rating and $102.0 target in Thursday, August 24 report. August 10 investment analysts at Morgan Stanley left the stock rating at "Equal-Weight" but raised the price target to $50.00 from $46.00. With 677,700 avg volume, 13 days are for Alnylam Pharmaceuticals Incorporated (NASDAQ:ALNY)'s short sellers to cover ALNY's short positions. Price Target plays a critical role when it comes to the analysis of a Stock.

Peter Algert decreased its stake in Orasure Technologies Inc (OSUR) by 88.88% based on its latest 2016Q4 regulatory filing with the SEC. The stock plummeted -5.79 percent over the past month and rose 96.82 percent year-to-date. 17,200 shares valued at $1.86 million were sold by VAN SANT R WILLIAM on Monday, May 1. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company's stock worth $413,811,000 after acquiring an additional 441,957 shares in the last quarter. The disclosure for this sale can be found here. The Return on Investment (ROI) ratio of Alnylam Pharmaceuticals, Inc. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates created to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. (NASDAQ:ALNY). D E Shaw And Com reported 215,426 shares or 0.01% of all its holdings.



Like this

loading...
loading...

Latest


12 September 2017
California challenges President Trump's end to young immigrant programme DACA
President Trump said he would end the DACA program if Congress hasn't acted within six months to enact it into law. In July, Becerra was among the attorneys general who wrote to Trump, urging him to retain the DACA program.

12 September 2017
Stephen Curry wants National Football League teams to 'freekaep'
Kaepernick became part of a lot of headlines when he chose to kneel during the playing of the Star Spangled Banner as an act of protest against racially-charged issues the country is facing.

12 September 2017
AMC Entertainment Holdings, Inc. (AMC) Closed its Previous Trade at $13.35
The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink . Press coverage about AMC Entertainment Holdings (NYSE:AMC) has been trending somewhat positive this week, according to Accern.

11 September 2017
Manchester United 'reserve No.7 shirt for Antoine Griezmann'
Atletico Madrid' 26-years-old star still in the MU wish list. He is quite a while being a long-time target for them. Let us know your thoughts in the comments.

11 September 2017
Leonardo DiCaprio would like to play Stan Lee in a biopic
The Power Rangers movie producers Marty Bowen and Wyck Godfrey are on board and we can expect more updates on this project soon. At the age of 94, many fans are rightly concerned about just how much longer Lee will be around to delight grateful fans.

11 September 2017
Madras HC dismisses plea against AIADMK general council meet
Speaking to ANI, Dhinakaran said If the Chief Minister of Tamil Nadu is not changed we are prepared to bring this government down. Lawmaker V Vetrivel, who filed the petition, has been fined Rs 1 lakh for wasting the court's time.

11 September 2017
A day after pro-Dileep statements, Sreenivasan's house 'blackened'
Talking to media, Sreenivasan refused to call the "black-oil" attack on his house, a repercussion of his pro-Dileep statements. Since then, many of his colleagues have been supporting him as they believe him to be innocent until proven guilty.

11 September 2017
Patient kills foreign Red Cross staffer in Afghanistan
The gunmen believed to be loyalists of the ISIS terrorist group also kidnapped a number of the ICRC staff member after the attack. Police told the BBC the men had disabilities, and had hidden guns in their plastic prosthetic legs.

11 September 2017
TheStreet Upgrades Alibaba Group Holding Limited (BABA) to "B-"
The United Kingdom-based Ahl Partners Llp has invested 0.05% in Buffalo Wild Wings (NASDAQ:BWLD). (NASDAQ:AAPL) for 9,254 shares. The Stock has shows volatility of 1.70% in recent 5 days and demonstrated volatility of 2.22% in last 30 days.

11 September 2017
Shares in Franco-Nevada Corporation (FNV) Acquired by KCG Holdings Inc
Finally, Edmond DE Rothschild Holding S.A. grew its stake in shares of Franco-Nevada Corporation by 0.8% in the second quarter. Advisory Services Network LLC raised its stake in shares of Franco-Nevada Corporation by 199.0% during the 2nd quarter.